This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tassi, E. Articles by Wellstein, A. Search for Related Content PubMed PubMed Citation Articles by Tassi, E. Articles by Wellstein, A.

Expression of a Fibroblast Growth Factor–Binding Protein during the Development of Adenocarcinoma of the Pancreas and Colon

¹ Lombardi Cancer Center, Georgetown University, Washington, District of Columbia and ² Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: Anton Wellstein, Lombardi Cancer Center, Georgetown University, Room E311, Research Building, 3970 Reservoir Road, Washington, DC 20057. Phone: 202-687-3672; Fax: 202-687-4821; E-mail: wellstea{at}georgetown.edu.

The activity of growth factors is crucial for tumor progression. We previously characterized a secreted fibroblast growth factor–binding protein (FGF-BP1) as a chaperone molecule, which enhances the biological functions of FGFs by releasing FGFs from the extracellular matrix. Here, we characterize the frequency and pattern of FGF-BP1 expression during the malignant progression of pancreas and colorectal carcinoma. For this, we generated monoclonal antibodies that detect FGF-BP1 protein in formalin-fixed, paraffin-embedded tissues and applied in situ hybridization to detect FGF-BP1 mRNA in adjacent tissue sections. FGF-BP1 protein and mRNA were found up-regulated (>70% positive) in parallel (r = 0.70, P < 0.0001) in colon adenoma (n = 9) as well as primary (n = 46) and metastatic (n = 71) colorectal cancers relative to normal colon epithelia (all P < 0.0001, versus normal). Similarly, pancreatitis (n = 17), pancreatic intraepithelial neoplasia (n = 80), and pancreatic adenocarcinoma (n = 67) showed a significant up-regulation of FGF-BP1 compared with normal pancreas (n = 42; all P < 0.0001, relative to normal). Furthermore, the biological activity of FGF-BP1 is neutralized by one of the antibodies, suggesting the potential for antibody-based therapeutic targeting. We propose that the up-regulation of the secreted FGF-BP1 protein during initiation of pancreas and colon neoplasia could make this protein a possible serum marker indicating the presence of high-risk premalignant lesions. (Cancer Res 2006; 66(2): 1191-8)

This article has been cited by other articles:

				W. Zhang, Y. Chen, M. R. Swift, E. Tassi, D. C. Stylianou, K. A. Gibby, A. T. Riegel, and A. Wellstein Effect of FGF-binding Protein 3 on Vascular Permeability J. Biol. Chem., October 17, 2008; 283(42): 28329 - 28337. [Abstract] [Full Text] [PDF]

				E. Tassi, S. Walter, A. Aigner, R. H. Cabal-Manzano, R. Ray, P. J. Reier, and A. Wellstein Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R775 - R783. [Abstract] [Full Text] [PDF]